AI Article Synopsis
- * It highlights the importance of improving quality of life for these patients through various treatment options, including advanced pharmacological approaches and newer revascularization strategies.
- * The review also evaluates the potential of angiogenetic and stem cell therapies, along with guidelines from the 2019 ESC for managing chronic coronary syndromes.
Article Abstract
Despite the use of anti-anginal drugs and/or percutaneous coronary interventions (PCI) or coronary artery bypass grafting, the proportion of patients with coronary artery disease who have daily or weekly angina ranges from 2% to 24%. Refractory angina refers to long-lasting symptoms (for >3 months) due to established reversible ischaemia, which cannot be controlled by escalating medical therapy with the use of 2nd- and 3rd-line pharmacological agents, bypass grafting, or stenting. While there is uncertain prognostic benefit, the treatment of refractory angina is important to improve the quality of life of the patients affected. This review focuses on conventional pharmacological approaches to treating refractory angina, including guideline directed drug combination and dosages. The symptomatic and prognostic impact of advanced and novel revascularization strategies such as chronic total occlusion PCI, transmyocardial laser revascularization, coronary sinus occlusion, radiation therapy for recurrent restenosis, and spinal cord stimulation are also covered and recommendations of the 2019 ESC Guidelines on the Diagnosis and Management of Chronic Coronary Syndromes discussed. Finally, the potential clinical use of current angiogenetic and stem cell therapies in reducing ischaemia and/or pain is evaluated.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/eurheartj/ehaa820 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bridging the Gender Gap in Cardiovascular Medicine: Addressing Drug Intolerances and Personalized Care for Women with Angina/Ischemia with Non-Obstructive Coronary Artery Disease.
J Cardiovasc Dev Dis
November 2024
Robert Bosch Krankenhaus, Department of Cardiology and Angiology, Auerbachstr. 110, 70376 Stuttgart, Germany.
Gender medicine has increasingly underscored the necessity of addressing sex-based differences in disease prevalence and management, particularly within cardiovascular conditions and drug intolerance. Women often present cardiovascular diseases distinctively from men, with a higher prevalence of non-obstructive coronary artery disease and varied ischemic manifestations, such as coronary microvascular dysfunction and epicardial or microvascular coronary spasm. This disparity is further exacerbated by elevated drug intolerance rates among women, influenced by hormonal, genetic, and psychosocial factors.
View Article and Find Full Text PDFSuccessful implantation of cardiac resynchronization therapy in a patient with coronary sinus reducer using proximal coronary sinus branches: a case report.
Eur Heart J Case Rep
December 2024
Cardiac Electrophysiology and Electrostimulation Unit, San Pietro Fatebenefratelli Hospital Rome, Via Cassia, 600, 00189 Rome, Italy.
Background: The coronary sinus reducer (CSR) is a therapeutic option for patients with coronary artery disease who are not eligible for further revascularization and experience refractory angina. Cardiac resynchronization therapy (CRT) improves symptoms and prognosis in heart failure with reduced ejection fraction, but the presence of a CSR may complicate left ventricular lead placement. Only four cases have been reported so far in this context.
View Article and Find Full Text PDFProcedural factors influencing successful coronary sinus reducer implantation for refractory angina: A single-centre experience.
Cardiovasc Revasc Med
December 2024
Royal Brompton Hospital, Guy's and St Thomas' NHS Foundation Trust, Sydney Street, Chelsea, London SW3 6NP, UK; National Heart and Lung Institute, Imperial College London, UK. Electronic address:
Background: Coronary sinus reducer (CSR) implantation is emerging as a novel effective percutaneous therapy for patients with refractory angina. Limited data exists examining the factors influencing successful CSR implantation. As CSR implantation becomes more widely adopted, a greater understanding of the procedural challenges which operators encounter is required.
View Article and Find Full Text PDFNew Directions in Coronary Revascularization for Refractory Angina: Gene Therapy and the Lizard Heart.
Semin Thorac Cardiovasc Surg
December 2024
Department of Surgery, Division of Cardiac Surgery, The Ohio State University, Columbus, Ohio. Electronic address:
Refractory angina is a debilitating disease with limited therapeutic options that is primarily caused by microvascular dysfunction and desertification. Towards addressing this unmet need, microvascular revascularization therapy has progressively evolved from the lizard heart inspired transmyocardial revascularization to precisely inducing vascular endothelial growth factor with gene therapy. Gene therapy with adenoviral vehicles or naked modified ribonucleic acid is safe and shows early signs of clinical promise but has not yet been proven effective due to gaps in optimization.
View Article and Find Full Text PDF[Current state of algology - pain medicine - in the Russian Federation].
Zh Vopr Neirokhir Im N N Burdenko
December 2024
JSC «K+31», Moscow, Russia.
Objective: To analyze the structure of care for patients with pain syndromes in the Russian Federation and possible improvement of these approaches.
Material And Methods: A detailed questionnaire was sent to 60 pain clinics. We received responses from 40 hospitals.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!